학술논문

XTX202, A TUMOR-SELECTIVE PROTEIN-ENGINEERED IL2, EXHIBITED ENHANCED ANTI-TUMOR ACTIVITY IN COMBINATION WITH CHECKPOINT INHIBITION IN MICE
Document Type
Journal
Source
JOURNAL FOR IMMUNOTHERAPY OF CANCER; NOV 2022, 10 pA878-pA878, 1p. Supplement: 2
Subject
Language
English
ISSN
20511426